Turing Pharmaceuticals chief executive Martin Shkreli bought more than 50% of KaloBios Pharmaceuticals Inc. (Nasdaq: KBIO) stock sending the stock price soaring $8.43 to $10.50.
Turing CEO buys majority stake in KaloBios
November 19, 2015 at 11:26 AM EST
